These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32194176)

  • 1. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
    Marafini I; Troncone E; Salvatori S; Monteleone G
    Pharmacol Res; 2020 May; 155():104757. PubMed ID: 32194176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-Beta signaling manipulation as potential therapy for IBD.
    Marafini I; Zorzi F; Codazza S; Pallone F; Monteleone G
    Curr Drug Targets; 2013 Nov; 14(12):1400-4. PubMed ID: 23489130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
    Spadaccini M; D'Alessio S; Peyrin-Biroulet L; Danese S
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
    Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense approach to inflammatory bowel disease: prospects and challenges.
    Marafini I; Di Fusco D; Calabrese E; Sedda S; Pallone F; Monteleone G
    Drugs; 2015 May; 75(7):723-30. PubMed ID: 25911184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.
    Laudisi F; Dinallo V; Di Fusco D; Monteleone G
    Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.
    Monteleone G; Kumberova A; Croft NM; McKenzie C; Steer HW; MacDonald TT
    J Clin Invest; 2001 Aug; 108(4):601-9. PubMed ID: 11518734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic targets for inflammatory bowel disease.
    Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
    J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases.
    Zorzi F; Angelucci E; Sedda S; Pallone F; Monteleone G
    Dig Liver Dis; 2013 Jul; 45(7):552-5. PubMed ID: 23287011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease.
    Ardizzone S; Bevivino G; Monteleone G
    Therap Adv Gastroenterol; 2016 Jul; 9(4):527-32. PubMed ID: 27366221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer.
    Troncone E; Marafini I; Stolfi C; Monteleone G
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
    Salari-Sharif P; Abdollahi M
    Curr Pharm Des; 2010; 16(33):3661-7. PubMed ID: 21128899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Smad7 in inflammatory bowel diseases.
    Monteleone G; Caruso R; Pallone F
    World J Gastroenterol; 2012 Oct; 18(40):5664-8. PubMed ID: 23155305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotides-A Novel Promising Therapeutic Option for IBD.
    Scarozza P; Schmitt H; Monteleone G; Neurath MF; Atreya R
    Front Pharmacol; 2019; 10():314. PubMed ID: 31068803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
    Catalan-Serra I; Brenna Ø
    Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials.
    Monteleone G; Stolfi C
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway-based approaches to the treatment of inflammatory bowel disease.
    Bamias G; Pizarro TT; Cominelli F
    Transl Res; 2016 Jan; 167(1):104-15. PubMed ID: 26408803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetomilast: new promise for phosphodiesterase-4 inhibitors?
    Bickston SJ; Snider KR; Kappus MR
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1845-9. PubMed ID: 23043390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.